Trial Profile
Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Ranging Study of Piromelatine in Patients With Mild Dementia Due to Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2020
Price :
$35
*
At a glance
- Drugs Piromelatine (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms ReCOGNITION
- Sponsors NEURIM Pharmaceuticals
- 25 Feb 2020 Status changed from active, no longer recruiting to completed.
- 20 Aug 2019 Planned End Date changed from 1 Apr 2019 to 30 Nov 2019.
- 20 Aug 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Nov 2019.